SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

09 Aug 2022 Evaluate
The Turnover for the quarter ended June 2022 of Rs. 613.40 millions increase by 69.17% from Rs. 362.60 millions.The Net Loss for the quarter ended June 2022 is Rs. -742.40 millions as compared to Net Loss of Rs. -234.70 millions of corresponding quarter ended June 2021 Operating profit Margin for the quarter ended June 2022 further decreased to -654.90% as compared to -152.60% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 613.40 362.60 69.17 613.40 362.60 69.17 2355.00 3435.60 -31.45
Other Income 65.30 41.50 57.35 65.30 41.50 57.35 125.70 207.40 -39.39
PBIDT -654.90 -152.60 329.16 -654.90 -152.60 329.16 -601.10 212.40 -383.00
Interest 24.70 17.80 38.76 24.70 17.80 38.76 70.40 75.20 -6.38
PBDT -679.60 -170.40 298.83 -679.60 -170.40 298.83 -671.50 137.20 -589.43
Depreciation 62.80 64.30 -2.33 62.80 64.30 -2.33 264.30 265.70 -0.53
PBT -742.40 -234.70 216.32 -742.40 -234.70 216.32 -935.80 -128.50 628.25
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.60 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.10 0.00
PAT -742.40 -234.70 216.32 -742.40 -234.70 216.32 -935.80 -144.10 549.41
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) -106.77 -42.08 153.69 -106.77 -42.08 153.69 -25.52 6.18 -512.86

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×